Roche: SARS-CoV-2 Rapid Antigen Test Nasal allows patient self-collection

  -- The SARS-CoV-2 Rapid Antigen Test Nasal uses a nasal swab to quickly and

      conveniently collect specimens from people suspected of having an active 
      infection 
 
   -- Nasal sampling allows for collection of the sample from the front area of 
      the nose instead of the nasopharynx resulting on a less invasive testing 
      experience for patients 
 
   -- The test also provides patients with the option to self-collect their 
      nasal sample 
 
Roche (SIX: RO, ROG; OTCQX: RHHBY) today 
announced it has obtained the CE mark for its new SARS-CoV-2 Rapid 
Antigen Test Nasal. The test will be available in countries accepting 
the CE mark by mid-February 2021. 
 
 
 
   In comparison to the existing Roche SARS-CoV-2 Rapid Antigen Test, the 
SARS-CoV-2 Rapid Antigen Test Nasal collects the sample from the front 
area of the nose instead of the nasopharynx, resulting in a simplified 
and faster testing procedure(1) . This testing method can help reduce 
overall patient discomfort, particularly in sensitive individuals such 
as children, elderly people and/or people with disabilities. 
 
 
 
   Besides being less invasive, the test also provides patients with the 
option to self-collect their nasal sample under the supervision of a 
healthcare professional. Through reduced physical contact, this method 
of testing can help to decrease the risk of exposure to the virus for 
healthcare professionals. Whether the test could also be used without 
supervision of a healthcare professional will depend on local regulatory 
requirements. 

https://www.marketscreener.com/quote/stock/ROCHE-HOLDING-AG-9364975/news/Press-Release-Roche-announces-the-upcoming-launch-of-the-SARS-CoV-2-Rapid-Antigen-Test-Nasal-allow-32328198/